The PROgnostic Value of unrequested Information in Diagnostic Imaging (PROVIDI) Study: rationale and design by M. J. A. Gondrie et al.
NEW STUDY
The PROgnostic Value of unrequested Information in Diagnostic
Imaging (PROVIDI) Study: rationale and design
M. J. A. Gondrie • W. P. Th. M. Mali •
C. F. M. Buckens • P. C. A. Jacobs •
D. E. Grobbee • Y van der Graaf
Received: 13 April 2010 / Accepted: 15 September 2010 / Published online: 2 October 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract We describe the rationale for a new study
examining the prognostic value of unrequested findings in
diagnostic imaging. The deployment of more advanced
imaging modalities in routine care means that such findings
are being detected with increasing frequency. However, as
the prognostic significance of many types of unrequested
findings is unknown, the optimal response to such findings
remains uncertain and in many cases an overly defensive
approach is adopted, to the detriment of patient-care.
Additionally, novel and promising image findings that are
newly available on many routine scans cannot be used to
improve patient care until their prognostic value is properly
determined. The PROVIDI study seeks to address these
issues using an innovative multi-center case-cohort study
design. PROVIDI is to consist of a series of studies inves-
tigating specific, selected disease entities and clusters.
Computed Tomography images from the participating hos-
pitals are reviewed for unrequested findings. Subsequently,
this data is pooled with outcome data from a central popu-
lation registry. Study populations consist of patients with
endpoints relevant to the (group of) disease(s) under study
along with a random control sample from the cohort. This
innovative design allows PROVIDI to evaluate selected
unrequested image findings for their true prognostic value in
a series of manageable studies. By incorporating unre-
quested image findings and outcomes data relevant to
patients, truly meaningful conclusions about the prognostic
value of unrequested and emerging image findings can be
reached and used to improve patient-care.
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Introduction
In this article the rationale and methods of the PROgnostic
Value of unrequested Information in Diagnostic Imaging
(PROVIDI) study are presented. It was designed to inves-
tigate the growing amount of unrequested information,
identified on diagnostic radiological examinations. PRO-
VIDI’s relatively large study sample and its innovative use
of a case-cohort design place it in an ideal position to
address some of the more challenging issues pertaining to
unrequested radiological findings.
Rationale
Advances in radiological imaging techniques have led to
scans of increasingly high resolution and contrast being
deployed ever more widely, with the Computed Tomog-
raphy (CT) [1] and Magnetic Resonance Imaging (MRI)
[2] modalities leading the way. CT in particular is being
deployed for a growing number of clinical indications and
over the last decade alone CT image quality has evolved
tremendously from single-section helical CT to the greater
spatial and temporal resolution offered by multi-detector
row CT (MDCT). 4-, 8- and 16-slice scanners are now
widely in use, 64- and 256-slice scanners are being intro-
duced into routine clinical practice whilst 320-slice scan-
ners are in late phases of testing [3].
The increasingly widespread use of higher quality CT in
routine diagnostic clinical care is causing a corresponding
increase in the numbers of unrequested findings being
detected, which previously would have gone unnoticed;
characterized as unrequested information which is unre-
lated to the initial scanning indication [4, 5]. As the
referrals for routine scanning are typically highly targeted
at investigating specific pathologies in specific organs,
there is plenty of scope for unrequested findings that are
not linked to these initial referrals. These referrals are
typically the only additional clinical information that
radiologists possess, adding to the uncertainty over how to
handle unrequested findings. Evidence from the literature
indicates that, on the whole, a large number of unrequested
findings are not addressed in routine clinical settings [6],
whilst others may be subject to aggressively defensive
follow-up [7, 8]. Due to their uncertain clinical signifi-
cance, such findings pose a novel challenge to radiologists
and referring clinicians alike.
Contributing to this trend of increasingly detected
unrequested information is the growing culture of medical
litigation wherein radiological lawsuits pertaining to mis-
sed diagnoses and perceived failure to initiate follow-up
investigations form a growing majority of the total [9].
This follow-up exposes patients to potential harm in
the form of unnecessary radiation exposure, invasive
procedures, the anxiety and stress associated with an
uncertain disease-state, as well as financial cost [10].
Additionally, to date the impact of emerging diagnostic
findings, such as arterial calcium scores and volumetric
analysis of lung nodules [11], are only partially understood
and go largely unutilized in routine care. The fact that
many potentially predictive findings, as unrequested
detected findings, may be available in some form for free
on routine scans makes the investigation of their imple-
mentation necessary. The potential for risk stratification
and preventative treatment for a range of disorders span-
ning from cardiovascular disease to osteoporosis using
unrequested imaging characteritics extracted from the
hodgepodge of routine scanning equipment and protocols
could be unlocked by demonstrating the prognostic utility
of this approach.
The question of how best to adapt to the growing
number of unrequested findings has engendered lively
debate amongst radiologists, with opinions ranging from
advocacy of maximal pursuit for and follow-up of all
available findings, to deliberately ignoring anatomical
regions and findings beyond the mandates of the scan
indication [12–15]. This debate takes place in the context
of the limited clinical information typically available to the
radiologist and such discussions are a consequence of
rapidly advancing techniques with attendant lack of
knowledge of their implications. Debate will continue until
follow-up studies are performed to investigate which
unrequested scan findings are significant and which find-
ings have no clinical impact. For these reasons, there is the
urgent need of follow-up studies in routine radiologic set-
tings; there have been but a few admirable attempts [10] at
collecting follow-up data on patients with unrequested
findings but virtually none investigating the prognostic
endpoints. The work carried out in screening settings may
not be representative for routine care settings due to for
example different hazards for experiencing outcome events
and concurrently, there is no basis for comparison between
routine-care settings and the radiological prognostic
research carried out so far in research settings using
screening populations.
The PROVIDI study is the first study that aims to
address these issues. It is designed as a longitudinal study,
linking unrequested information detected on routine diag-
nostic Chest CT scans to major health outcomes via
national health registries. In doing so we are able to
identify those readily accessible unrequested findings that
are prognostically relevant and sort them from findings that
have little or no value to the patient (Fig. 1). This may
allow clinical radiologists to contribute more generally
than before to patient care by more effectively utilizing the
increasing amount of diagnostic information available,
thereby increasing the efficiency of health care.




The PROVIDI study is designed as a multi-center retro-
spective case-cohort study. The cohort consists of subjects
with routinely made chest CT scans obtained from eight
participating hospitals in the Netherlands (Elkerliek Hos-
pital (Elkerliek), Gelre Hospital (Gelre), St. Antonius
Hospital (Antonius), Academic Medical Center Amster-
dam (AMC), VU University Medical Center (VUMC),
University Medical Center Groningen (UMCG), Academic
Hospital Maastricht (AZM), and University Medical Cen-
ter Utrecht (UMCU)), of which the latter five are tertiary
referral centers. A case-cohort design offers significant
gains in efficiency over a standard cohort study [16], at
the cost of increased complexity in data analysis and the
addition of a theoretical layer of assumptions about the
uniformity of the cohort. The crucial difference from a
normal cohort study is that a random control sample of the
cohort is selected at baseline to represent the cohort,
making it unnecessary to analyse the whole cohort. Each
(cluster of) unrequested finding of interest can then be
studied in such an individual sub study that combines the
cases that suffered outcome(s) relevant to that finding
during follow-up with a new random sample of controls
that did not. The control group is to be randomly sampled
so that the group is twice as large as the case group for the
individual sub study. This permits the use of the PROVIDI
cohort in the investigation of the prognostic value of a
range of unrelated unrequested findings, as well giving
researchers the freedom to pursue unforeseen candidate
findings as they emerge. Valid absolute risks, which are
indispensable to prognostic research, can be readily
calculated.
It was not possible to evaluate the extent of clinical
follow-up undergone by patients as a result of unrequested
findings with this study design. We did not consider this to
Fig. 1 Objective of the
PROVIDI-study
Table 1 Textbox, explanation of pilot study
Pilot study
A pilot study was conducted to investigate if the indication categories could be used to identify patients with a very bad prognosis a priori
For this pilot study, all patients, older than 40 years and undergoing thoracic CT at the University Medical Center Utrecht and Academic
Hospital Maastricht were included. Information about mortality was gathered through linkage with the National Death Registry after
complete follow-up
A comparison was made between patients who deceased within 6 months of follow–up and patients who deceased after 6 months of follow-up
Patients with indication categories ‘Suspected primary lung cancer (including mesothelioma)’ and ‘distant metastatic disease from other types
of cancer (excluding haematological malignancies)’ had an average mortality rate within 6 months of 33.9%. This was much higher
compared to the mortality rate for the other indication categories (mean 10.4%, P \ 0.001)
We concluded that the indication categories can discriminate well between patients’ prognoses and could be used to exclude patients with a
bad prognosis a priori
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be a serious limitation as this is rare in practice [6] and at
any rate, it would cause an underestimation of the prog-
nostic effect (as those receiving preventative therapies are
probably less likely to experience the outcome of interest).
The PROVIDI study was approved by the Medical
Ethics Committee of the University Medical Center Utr-
echt. The need for written informed consent was waived for
all patients due to the retrospective design of this study. A
privacy protocol was implemented to ensure that no patient
information would be visible whilst reading CT scans and
no additional information could be obtained from patient’s
medical records and no patient would be contacted as a
result of this study.
Study subjects
All patients aged 40 years and older who were referred to
one of the participating hospitals with an indication for a
chest MDCT between January 2002 and the end of
December 2005 were evaluated for inclusion in the PRO-
VIDI study (N = 23.443). Patients with suspected primary
lung cancer (including mesothelioma) or distant metastatic
disease from other types of cancer (excluding haemato-
logical malignancies), 9.077 cases in all, were excluded, on
the basis that it is highly unlikely that detection of unre-
quested imaging findings will alter clinical decision mak-
ing in patients with such a poor prognosis. This selection
was first fully evaluated in a pilot study (Table 1, textbox,
pilot study). Consequently, the PROVIDI cohort consists of
14.366 patients, and an equal number of chest CT’s. In
cases where patients underwent more than one chest CT
examination, only the first CT scan of the series was used
for analysis. The chest CT’s were obtained with 2-, 4-, 8-,
16-, 32- or 64-slice scanners of different vendors. All types
of chest CT protocols, including contrast and non-contrast
scans, were eligible for the PROVIDI study. The CT scans
were initially assessed by local hospital radiologists, con-
sistent with routine practice. Subsequently, anonymous
copies of all images were stored on disk and transferred to
the University Medical Center Utrecht. Patient character-
istics and information on type of CT protocol used,
including section thickness, tube voltage (kVp), tube load
(mAs), and the use of a contrast agent, was abstracted from
CT reports by a research physician, who also assessed the
CT indication from the CT reports.
Image findings
The specific candidate image findings will differ for each
individual study investigating different specific groupings
of disease entities and will be selected for their potential
prognostic value, as suggested by the available literature
and expert opinions from experienced radiologists as well
as other clinical specialists and epidemiologists. CT scans
will be reviewed, blinded for general scan parameters, CT
indication and the outcome status, at a computer worksta-
tion, by trained research physicians and supervised by an
experienced chest radiologist. Images are to be viewed at
Fig. 2 Examples of
unrequested scan findings.
Upper left non-contrast CT
image, lower left contrast CT
image, upper right CT image in
lung setting, lower right contrast
CT image in mediastinum
setting. a calcifications in Left
Main coronary artery and Left
Anterior Descending artery,
b calcification in descending
thoracic Aorta, c: Irregular
descending thoracic Aorta with
calcification, d diameter of left
ventricle, e diameter of heart,
f Lung emphysema,
g bronchiectasia, h Calcificated
plaque in ascending thoracic
Aorta, i enlarged lymph node,
j Pleural effusion
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standard lung, soft tissue, and bone settings, which are
also readily available to radiologists in clinical practice.
Reproducibility of image findings will be evaluated and
must be sufficient. Some examples of the types of candi-
date unrequested scan findings are listed in Fig. 2.
Endpoints
Main endpoints of the PROVIDI study—established after a
first initial linkage—are listed in Table 2. Ideal endpoints
would be prevalent diseases in with a major clinical impact
and can be treated preventively when diagnosed at an early
stage. The endpoints were ascertained through linkage with
the National Death Registry and the National Registry of
Hospital Discharge Diagnoses for the period January 2002-
December 2006. Research showed that the quality of these
databases was acceptable [17, 18]. Patients were identified
through a combination of a patient’s date of birth, sex, and
zip code, using a validated probabilistic method [17, 19,
20]. In these databases, cause of death and the occasion of
hospitalization are coded according to the International
Classification of Disease, 9th [21] and 10th revision [22].
In the initial linkage, performed at a mean followup of
17 months, a total 5.225 out of the 14.366 patient cohort
experienced a valid endpoint (Table 2). Note that this ini-
tial overview gives only a global indication of the numbers
(here death prevailed over admission) and will be updated
for each sub study to be performed.
Evaluation of data
PROVIDI will consist of a series of studies investigating
potentially predictive scan findings for specific groupings
of disease entities (e.g. cardiovascular diseases). The study
Table 2 Outcome events and




classification of disease, CvV
Intervention classification score
Outcome events ICD [1] Codes Initial numbers
Mortality
All cause mortality All codes 3677
Hospital admissions
Cardiovascular disease 659
Ischemic heart disease ICD9 410–414
Cerebrovascular diseases ICD9 431, 434–438
Thoracic aortic aneurysm ICD9 441
Peripheral arterial disease ICD9 443,444
Cardiac valve disease ICD9 424
Sudden cardiac death ICD9 427
Pericarditis ICD9 420,423
Interventions ICD9-CvV 5360–3, 5369, 5350–5354,
5380–3, 5385, 5399
Pulmonary embolism ICD9 4151 69
Neoplasmata 375
Bronchus, lung, thymus, heart, oesophagus ICD9 162–164, 150
Thyroid ICD9 193, 226
Hodgkin ICD9 201,
Non-Hodgkin ICD9 2020
Other mediastinal structures ICD9 1642–9, 2125
(Struma) ICD9 240–242 2126,
Pulmonary disease 392
Chronic obstructive lung disease ICD9 490, 4912, 4919, 4939, 496
Bronchiectasis ICD9 494
Pulmonary emphysema ICD9 492
Pulmonary fibrosis ICD9 515
Muskuloskeletal disease 53
Fracture of hip ICD9 820
Fracture of spine ICD9 805
Osteoporosis and osteoporotic fractures ICD9 733
Intervertebral disc disease ICD9 722
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populations of these studies will consist of the patients that
suffered the relevant disease(s) under study during the
follow-up period, as well as a random sample of patients
from the PROVIDI cohort (the sub-cohort). In each of
these studies, patients with a reported CT indication
directly related to the disease under study will be excluded,
to ensure that the image findings under study can legiti-
mately be defined as unrequested information, in keeping
with the stated goals of PROVIDI. (Table 3, textbox,
example study population) Fig. 3 shows the flowchart of
the PROVIDI design.
We intend to analyse the scan findings both univariately
and multivariately under study using Cox proportional
hazard models, the most widely used statistical model for
survival outcome in medical research. In multivariate
analysis infromation readily available to radiologists in
routine care (age, gender, CT indication, scanning param-
eters and quality) will be incorporated. The hazard ratios
and standard errors will be modified based on robust var-
iance estimates. These adaptations are to be carried out
using the method according to Prentice, in which all sub
cohort members are equally weighted [16]. Cases outside
the sub cohort are not to be weighted before failure and at
failure receive the same weight as members of the sub
cohort. This method has been shown to resemble most
closely estimates from a full-cohort analysis [23], without
requiring a full analysis.
Discussion
Investigating which image findings have prognostic value
and—perhaps more importantly—which findings do not, is
the first step in a process that has great potential to improve
clinical care. The findings of the PROVIDI study will be of
Table 3 Textbox, example study population
Example study population
The study population for a study investigating the prognostic value of
unrequested detected image findings that may be predictive for
cardiovascular disease will consist of all patients that experienced a
cardiovascular event during follow-up plus a random sample from
the PROVIDI cohort. Patients with a cardiovascular indication for
obtaining the chest CT are excluded, making sure that the image
findings under study are truly unrequested
Fig. 3 Flowchart of PROVIDI study. Question mark indicates that these numbers differ per conducted study within PROVIDI
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great interest to radiologists, but also to referring physi-
cians. The unique longitudinal study design, that places
outcomes that matter to patients at its heart, gives this study
the potential to meaningfully quantify the uncertainties
facing diagnosticians and protect patients from potential
over-diagnosis and over treatment. To illustrate: in the face
of an absence of research investigating patient outcomes in
routine-care, non-screening settings, radiologists are regu-
larly responding defensively with exhaustive follow-up. An
illustrative example is that of lung nodules, which are
routinely detected on thoracic CT scans of all types, and
which are frequently followed-up, despite evidence point-
ing to a low yield of significant pathology, at least in
research/screening settings [7, 8].
By drawing on non-screening, routine clinical data it
may both alleviate the dearth in radiological routine-care
outcome data and serve as a basis for comparison with
previous evidence from screening populations. A conse-
quence of this study design is that patients at risk for a
certain outcome will be identified using these models by
radiologists while they may be already identified as such by
other specialists, resulting in an overestimation of the
clinical impact of certain incidental findings. Such double
risk stratification would not have any negative effect for
patients: the high risk indication from a radiologist is
obtained freely (without additional radioation exposure)
and can serve as a stimulus to verify whether optimal
treatment has been initiated. In some cases this treatment is
already optimal and a referring clinician can then ignore
the ‘red flag’ if not, the referring specialist can consider
additional investigations or start preventative treatment.
Translating the insights that might be gained from this
study into clinical practice remains beyond the scope and
means of PROVIDI itself but constitutes a crucial next
step. Future clinical studies prospectively evaluating the
efficacy and feasibility of implementing changes to clinical
practice based upon PROVIDI’s findings could demon-
strate the benefit of fully utilizing the potential of modern
scanning technology.
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